Povidone Iodine Solution

Add Info

Povidone Iodine Solution Recall

Get an alert when a recall is issued.

Ask a Question

Questions & Answers

Add Info

Side Effects & Adverse Reactions

Warnings

For external use only

Avoid use on persons allergic to iodine

Stop using this product and ask a doctor if

Skin shows symptoms of irritation, sensitivity, redness, pain or swelling

Add Info

Legal Issues

There is currently no legal information available for this drug.

Add Info

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Add Info

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

Add Info

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Add Info

Uses

Directions

Patient preoperative prep

apply ample amount of gel to sponge

Scrub using a circular motion, starting at incision and move outward

Blot excess with sterile towel

Use full strength as a scrub and/or paint

Add Info

History

There is currently no drug history available for this drug.

Add Info

Other Information

There are no additional details available for this product.

Sources

Povidone Iodine Solution Manufacturers

Jiangsu Province Jianerkang Medical Dressing Co. ,ltd.

Povidone Iodine Solution | Jiangsu Province Jianerkang Medical Dressing Co. ,ltd.

There is currently no dosage information available for this product. We apologize for any inconvenience.

No Recall
Jiangsu Province Jianerkang Medical Dressing Co. ,ltd.

Povidone Iodine Solution | Jiangsu Province Jianerkang Medical Dressing Co. ,ltd.

There is currently no dosage information available for this product. We apologize for any inconvenience.

No Recall
Jiangsu Province Jianerkang Medical Dressing Co. ,ltd.

Povidone Iodine Solution | Jiangsu Province Jianerkang Medical Dressing Co. ,ltd.

There is currently no dosage information available for this product. We apologize for any inconvenience.

No Recall
Jiangsu Province Jianerkang Medical Dressing Co. ,ltd.

Povidone Iodine Solution | Jiangsu Province Jianerkang Medical Dressing Co. ,ltd.

There is currently no dosage information available for this product. We apologize for any inconvenience.

No Recall
James Alexander Corporation

Povidone Iodine Solution | James Alexander Corporation

Directions: one swab reverse cardboard sleeve then crush at dot between thumb and forefinger. Allow solution to saturate tip and apply solution to injury.

No Recall
Qualitest Pharmaceuticals

Povidone Iodine Solution | American Health Packaging

Carbamazepine suspension in combination with liquid chlorpromazine or thioridazine results in precipitate formation, and, in the case of chlorpromazine, there has been a report of a patient passing an orange rubbery precipitate in the stool following coadministration of the two drugs (see PRECAUTIONS, Drug Interactions). Because the extent to which this occurs with other liquid medications is not known, carbamazepine suspension should not be administered simultaneously with other liquid medications or diluents.

Monitoring of blood levels has increased the efficacy and safety of anticonvulsants (see PRECAUTIONS, Laboratory Tests). Dosage should be adjusted to the needs of the individual patient. A low initial daily dosage with a gradual increase is advised. As soon as adequate control is achieved, the dosage may be reduced very gradually to the minimum effective level. Medication should be taken with meals.

Since a given dose of carbamazepine suspension will produce higher peak levels than the same dose given as the tablet, it is recommended to start with low doses (children 6 to 12 years: ½ teaspoon q.i.d.) and to increase slowly to avoid unwanted side effects.

Conversion of patients from oral carbamazepine tablets to carbamazepine suspension: Patients should be converted by administering the same number of mg per day in smaller, more frequent doses (i.e., b.i.d. tablets to t.i.d. suspension).

Carbamazepine extended-release is an extended-release formulation for twice-a-day administration. When converting patients from carbamazepine conventional tablets to carbamazepine extended-release, the same total daily mg dose of carbamazepine extended-release should be administered. Carbamazepine extended-release tablets must be swallowed whole and never crushed or chewed. Carbamazepine extended-release tablets should be inspected for chips or cracks. Damaged tablets, or tablets without a release portal, should not be consumed. Carbamazepine extended-release tablet coating is not absorbed and is excreted in the feces; these coatings may be noticeable in the stool.

Epilepsy (SEE INDICATIONS AND USAGE)

Adults and children over 12 years of age – Initial: Either 200 mg b.i.d. for tablets and extended-release tablets, or 1 teaspoon q.i.d. for suspension (400 mg/day). Increase at weekly intervals by adding up to 200 mg/day using a b.i.d. regimen of carbamazepine extended-release or a t.i.d. or q.i.d. regimen of the other formulations until the optimal response is obtained. Dosage generally should not exceed 1000 mg daily in children 12 to 15 years of age, and 1200 mg daily in patients above 15 years of age. Doses up to 1600 mg daily have been used in adults in rare instances. Maintenance: Adjust dosage to the minimum effective level, usually 800 to 1200 mg daily.

Children 6 to 12 years of age – Initial: Either 100 mg b.i.d. for tablets or extended-release tablets, or ½ teaspoon q.i.d. for suspension (200 mg/day). Increase at weekly intervals by adding up to 100 mg/day using a b.i.d. regimen of carbamazepine extended-release or a t.i.d. or q.i.d. regimen of the other formulations until the optimal response is obtained. Dosage generally should not exceed 1000 mg daily. Maintenance: Adjust dosage to the minimum effective level, usually 400 to 800 mg daily.

Children under 6 years of age – Initial: 10 to 20 mg/kg/day b.i.d. or t.i.d. as tablets, or q.i.d. as suspension. Increase weekly to achieve optimal clinical response administered t.i.d. or q.i.d. Maintenance: Ordinarily, optimal clinical response is achieved at daily doses below 35 mg/kg. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the therapeutic range. No recommendation regarding the safety of carbamazepine for use at doses above 35 mg/kg/24 hours can be made.

Combination Therapy: Carbamazepine may be used alone or with other anticonvulsants. When added to existing anticonvulsant therapy, the drug should be added gradually while the other anticonvulsants are maintained or gradually decreased, except phenytoin, which may have to be increased (see PRECAUTIONS, Drug Interactions, and Pregnancy Category D).

Trigeminal Neuralgia (SEE INDICATIONS AND USAGE)
Initial: On the first day, either 100 mg b.i.d. for tablets or extended-release tablets, or ½ teaspoon q.i.d. for suspension, for a total daily dose of 200 mg. This daily dose may be increased by up to 200 mg/day using increments of 100 mg every 12 hours for tablets or extended-release tablets, or 50 mg (½ teaspoon) q.i.d. for suspension, only as needed to achieve freedom from pain. Do not exceed 1200 mg daily. Maintenance: Control of pain can be maintained in most patients with 400 to 800 mg daily. However, some patients may be maintained on as little as 200 mg daily, while others may require as much as 1200 mg daily. At least once every 3 months throughout the treatment period, attempts should be made to reduce the dose to the minimum effective level or even to discontinue the drug.
* Tablet = Chewable or conventional tablets
Dosage Information

Initial Dose

Subsequent Dose

Maximum Daily Dose

Indication

Tablet*

Extended-Release Tablets

Suspension

Tablet*

Extended-Release Tablets

Suspension

Tablet*

Extended-Release Tablets

Suspension

Epilepsy
Under 6 yr

10-20 mg/kg/day
b.i.d. or t.i.d.

10-20 mg/kg/day
q.i.d.

Increase weekly to achieve optimal clinical response, t.i.d. or q.i.d.

Increase weekly to achieve optimal clinical response, t.i.d. or q.i.d.

35 mg/kg/24 hr (see Dosage and Administration section above)

35 mg/kg/24 hr (see Dosage and Administration section above)

6-12 yr

100 mg b.i.d.
(200 mg/day)

100 mg b.i.d.
(200 mg/day)

½ tsp q.i.d.
(200 mg/day)

Add up to 100 mg/day at weekly intervals, t.i.d. or q.i.d.

Add 100 mg/day at weekly intervals, b.i.d.

Add up to 1 tsp (100 mg)/day at weekly intervals, t.i.d. or q.i.d.

1000 mg/24 hr

Over 12 yr

200 mg b.i.d.
(400 mg/day)

200 mg b.i.d.
(400 mg/day)

1 tsp q.i.d.
(400 mg/day)

Add up to 200 mg/day at weekly intervals, t.i.d. or q.i.d.

Add up to 200 mg/day at weekly intervals, b.i.d.

Add up to 2 tsp (200 mg)/day at weekly intervals, t.i.d. or q.i.d.

1000 mg/24 hr (12-15 yr)
1200 mg/24 hr (>15 yr)
1600 mg/24 hr (adults, in rare instances)

Trigeminal Neuralgia

100 mg b.i.d.
(200 mg/day)

100 mg b.i.d.
(200 mg/day)

½ tsp q.i.d.
(200 mg/day)

Add up to 200 mg/day in increments of 100 mg every 12 hr

Add up to 200 mg/day in increments of 100 mg every 12 hr

Add up to 2 tsp (200 mg)/day
in increments of 50 mg
(½ tsp) q.i.d.

1200 mg/24 hr

No Recall
Major Pharmaceuticals

Povidone Iodine Solution | Major Pharmaceuticals

As a first aid antiseptic
clean affected area apply a small amount of this product to the area1 to 3 times daily may be covered with a sterile bandage, if bandaged let dry.
For preoperative patient skin preparation

clean area apply to operative site prior to surgery using the applicator

No Recall